

# Hans Skovgaard Poulsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10503592/publications.pdf>

Version: 2024-02-01

62  
papers

2,027  
citations

279798

23  
h-index

243625

44  
g-index

62  
all docs

62  
docs citations

62  
times ranked

3276  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 206-218.	4.6	7
2	Indirect assessment of tumor-infiltrating lymphocyte activity in serum for predicting outcome in patients with glioblastoma treated with immunotherapy in the recurrent setting. <i>Journal of Clinical Oncology</i> , 2022, 40, 2059-2059.	1.6	0
3	Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab072.	0.7	4
4	A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution. <i>Frontiers in Oncology</i> , 2021, 11, 597587.	2.8	10
5	Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters. <i>Cell Cycle</i> , 2021, 20, 702-715.	2.6	6
6	ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. <i>Pharmacogenomics Journal</i> , 2020, 20, 213-219.	2.0	9
7	Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. <i>Molecular Oncology</i> , 2020, 14, 964-973.	4.6	2
8	Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40. <i>Frontiers in Oncology</i> , 2020, 10, 478.	2.8	11
9	Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study. <i>Oncotarget</i> , 2019, 10, 4397-4406.	1.8	27
10	Health-related quality of life and caregiver perspectives in glioblastoma survivors: a mixed-methods study. <i>BMJ Supportive and Palliative Care</i> , 2019, , bmjssc-2019-001777.	1.6	4
11	Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). <i>Neuro-Oncology</i> , 2019, 21, 1595-1606.	1.2	37
12	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268.	3.8	45
13	EPID-06. IMMUNE-RELATED PLASMA BIOMARKERS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi75-vi75.	1.2	0
14	EPID-13. IDENTIFICATION OF PROGNOSTIC MARKERS IN A COHORT OF CONSECUTIVE NON-SELECTED GLIOBLASTOMA PATIENTS RECEIVING STANDARD THERAPY. <i>Neuro-Oncology</i> , 2019, 21, vi77-vi77.	1.2	0
15	ATIM-01. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; A TRANSLATIONAL TRIAL IN PROGRESS. <i>Neuro-Oncology</i> , 2019, 21, vi1-vi1.	1.2	0
16	Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 1425.	2.8	30
17	Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. <i>Cancer Investigation</i> , 2018, 36, 165-174.	1.3	5
18	Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B. <i>Molecular Oncology</i> , 2018, 12, 406-420.	4.6	56

#	ARTICLE	IF	CITATIONS
19	Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. <i>Journal of Neuro-Oncology</i> , 2018, 137, 533-542.	2.9	19
20	Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors. <i>Cancer Investigation</i> , 2018, 36, 512-519.	1.3	9
21	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145.	3.8	41
22	DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 679.	4.1	19
23	Patterns of failure for patients with glioblastoma following O-(2-[ <sup>18</sup> F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 122, 380-386.	0.6	30
24	Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. <i>Radiotherapy and Oncology</i> , 2017, 125, 223-227.	0.6	21
25	Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. <i>Acta Oncologica</i> , 2017, 56, 1776-1785.	1.8	17
26	Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. <i>BMC Cancer</i> , 2017, 17, 278.	2.6	16
27	Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 21-32.	4.4	52
28	The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 373-381.	6.4	54
29	DRES-01. ROLE OF HISTONE LYSINE DEMETHYLASE KDM2B IN GLIOBLASTOMA TUMOR CELL MAINTENANCE AND CHEMORESISTANCE. <i>Neuro-Oncology</i> , 2017, 19, vi63-vi64.	1.2	0
30	Presentation of Two Cases with Early Extracranial Metastases from Glioblastoma and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.3	14
31	Hallmarks of glioblastoma: a systematic review. <i>ESMO Open</i> , 2016, 1, e000144.	4.5	122
32	Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. <i>Radiotherapy and Oncology</i> , 2016, 121, 132-137.	0.6	31
33	Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. <i>Molecular Oncology</i> , 2016, 10, 1160-1168.	4.6	22
34	Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. <i>Cancer Cell International</i> , 2016, 16, 34.	4.1	8
35	Comparison of 18F-FET and 18F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma. <i>Nuclear Medicine and Biology</i> , 2016, 43, 198-205.	0.6	10
36	Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. <i>Acta Oncologica</i> , 2016, 55, 418-422.	1.8	11

#	ARTICLE	IF	CITATIONS
37	ANGI-11VEGF-C CONTRIBUTES TO AUTOCRINE VEGFR2 SIGNALING AND AFFECTS CELL VIABILITY AND TUMOR GROWTH IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v43.2-v43.	1.2	0
38	EPID-28PROGNOSTIC AND PREDICTIVE BIOMARKERS IN RECURRENT WHO GRADE 3 GLIOMA PATIENTS TREATED WITH BEVACIZUMAB AND IRINOTECAN. <i>Neuro-Oncology</i> , 2015, 17, v84.2-v84.	1.2	0
39	MTR-18PREDICTIVE BIOMARKERS OF BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2015, 17, v128.2-v128.	1.2	0
40	18F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PlGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma. <i>PLoS ONE</i> , 2015, 10, e0115315.	2.5	8
41	ANGI-15COMBINED TARGETING OF NOTCH AND EGFR DISPLAY ADDITIVE INHIBITORY EFFECTS ON ANGIOGENESIS AND SURVIVAL IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v44.2-v44.	1.2	0
42	ANGI-05CORRELATION BETWEEN VEGF AND YKL-40 TISSUE EXPRESSION AND PLASMA LEVELS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v41.5-v42.	1.2	0
43	The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. <i>Cancer Management and Research</i> , 2014, 6, 373.	1.9	32
44	Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature. <i>Cancer Biology and Therapy</i> , 2014, 15, 862-877.	3.4	9
45	Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential. <i>Cancer Biology and Therapy</i> , 2014, 15, 216-224.	3.4	30
46	Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. <i>BMC Cancer</i> , 2013, 13, 402.	2.6	68
47	Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. <i>Nuclear Medicine and Biology</i> , 2011, 38, 509-515.	0.6	15
48	A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue. <i>Results in Pharma Sciences</i> , 2011, 1, 49-56.	4.2	12
49	Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. <i>Journal of Neuro-Oncology</i> , 2011, 104, 639-646.	2.9	131
50	Cell adhesion and EGFR activation regulate EphA2 expression in cancer. <i>Cellular Signalling</i> , 2010, 22, 636-644.	3.6	55
51	The functional role of Notch signaling in human gliomas. <i>Neuro-Oncology</i> , 2010, 12, 199-211.	1.2	105
52	Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. <i>Neuro-Oncology</i> , 2010, 12, 508-16.	1.2	149
53	Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. <i>Acta Oncol</i> , 2009, 48, 52-58.	1.8	94
54	Identification of novel peptide ligands for the cancer-specific receptor mutation EGFRvIII using a mixture-based synthetic combinatorial library. <i>Biopolymers</i> , 2009, 91, 201-206.	2.4	24

#	ARTICLE	IF	CITATIONS
55	Improved Response by Co-targeting EGFR/EGFRvIII and Src Family Kinases in Human Cancer Cells. <i>Cancer Investigation</i> , 2009, 27, 178-183.	1.3	11
56	Activation of the EGFR Gene Target EphA2 Inhibits Epidermal Growth Factor-Induced Cancer Cell Motility. <i>Molecular Cancer Research</i> , 2007, 5, 283-293.	3.4	114
57	Mechanisms for oncogenic activation of the epidermal growth factor receptor. <i>Cellular Signalling</i> , 2007, 19, 2013-2023.	3.6	250
58	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 62, 362-362.	2.9	0
59	Dosimetry and growth hormone deficiency following cranial irradiation of childhood brain tumors. <i>Medical and Pediatric Oncology</i> , 1999, 33, 564-571.		28
60	Dosimetry and growth hormone deficiency following cranial irradiation of childhood brain tumors. <i>Medical and Pediatric Oncology</i> , 1999, 33, 564.	1.0	2
61	Diagnostic reliability of combined physical examination, mammography, and fine-needle puncture (triple-test) in breast tumors: A prospective study. <i>Cancer</i> , 1987, 60, 1866-1871.	4.1	135
62	Orphan drugs in glioblastoma multiforme: a review. <i>Orphan Drugs: Research and Reviews</i> , 0, , 83.	0.6	6